Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients

• DOI: 10.1016/j.celrep.2016.04.015
• Publication Date: 2016-04-30T21:54:20Z
• Authors: Gabriela Jiménez-...; Mar Martínez-Lozano; Nicklas Bassani; August Vidal; María Ochoa-de-Olza; Cristina Suárez; Xavier García-del...; Joan Carles; Francesc Viñals; Mariona Graupera; Stefano Indraccolo; Oriol Casanovas
• Keywords: Male; 0301 basic medicine; Cancer cells; Indoles; QH301-705.5; Mice, Nude; Angiogenesis Inhibitors; Càncer de ronyó; 03 medical and health sciences; Report; Sunitinib; Animals; Humans; Pyrroles; Everolimus; Biology (General); Carcinoma, Renal Cell; Neovascularization; Resistència als medicaments; Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Male; Mice, Nude; Phenotype; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Drug Resistance, Neoplasm; Xenograft Model Antitumor Assays; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays; Kidney Neoplasms; Angiogènesi; 3. Good health; Renal cancer; Phenotype; Drug Resistance, Neoplasm; Drug resistance; Cèl·lules canceroses; Signal Transduction

Antiangiogenic drugs are used clinically for treatment of renal cell carcinoma (RCC) as a standard first-line treatment. Nevertheless, these agents primarily serve to stabilize disease, and resistance eventually develops concomitant with progression. Here, we implicate metabolic symbiosis between tumor cells distal and proximal to remaining vessels as a mechanism of resistance to antiangiogenic therapies in patient-derived RCC orthoxenograft (PDX) models and in clinical samples. This metabolic patterning is regulated by the mTOR pathway, and its inhibition effectively blocks metabolic symbiosis in PDX models. Clinically, patients treated with antiangiogenics consistently present with histologic signatures of metabolic symbiosis that are exacerbated in resistant tumors. Furthermore, the mTOR pathway is also associated in clinical samples, and its inhibition eliminates symbiotic patterning in patient samples. Overall, these data support a mechanism of resistance to antiangiogenics involving metabolic compartmentalization of tumor cells that can be inhibited by mTOR-targeted drugs.